Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

PHATBullishEarningsShort Term

High materiality9/10

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

StockNews.AIJul 30, 6:59 AM EDT1 source

Trading thesisImportance 9/10

PHAT likely to rally into 2H2026 on VOQUEZNA growth and Phase 3/EoE catalysts.

AI summary

What happened and why it matters

Phathom posted Q2 2026 net revenues of $74.3M, up 88% YoY, and achieved operating profitability excluding stock-based compensation. VOQUEZNA adoption accelerated with 1.7M total prescriptions filled by July 17, 2026 and 325k in Q2. The company updated 2026 guidance and outlined Phase 3 as-needed NERD program with first subject enrollment expected in Q4 2026, signaling potential long-term expansion.

Q2 2026 net revenues rose to $74.3M, up 88% YoY, signaling accelerating top-line growth.
Phase 3 as-needed NERD program enrollment expected in Q4 2026 could expand VOQUEZNA label.
Updated 2026 guidance lowered range concerns but maintains growth trajectory.
Total VOQUEZNA prescriptions ~1.7M as of July 17, 2026; 64% covered prescriptions.

Sentiment rationale

Solid top-line growth, cost discipline, and first-step profitability ex-SBC reduce risk; ongoing Phase 3/Nerd and EoE readouts offer multiple catalysts; 1.7M prescriptions imply durable adoption.

Key facts

01
PHAT Q2 2026 net revenues $74.3M, up 88% YoY. VOQUEZNA adoption accelerates.
02
Q2 operating expenses $63.1M; down 33% YoY. Cost discipline ongoing.
03
VOQUEZNA prescriptions filled ~1.7M total by July 17, 2026; Q2 ~325k, +88% YoY.
04
Phase 3 as-needed VOQUEZNA for NERD; first subject enrollment expected Q4 2026.
05
FY2026 guidance updated: net revenue $310–325M; non-GAAP OpEx $235–245M.

Earnings

Category: Earnings. The release combines quarterly results with pipeline updates and forward guidance, shaping near-term sentiment on PHAT and establishing longer-term growth catalysts around VOQUEZNA and potential label expansions.